

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 401/12, 235/28, 513/04</b>		A1	(11) International Publication Number: <b>WO 98/40378</b> (43) International Publication Date: 17 September 1998 (17.09.98)
<p>(21) International Application Number: <b>PCT/DK98/00059</b></p> <p>(22) International Filing Date: 16 February 1998 (16.02.98)</p> <p>(30) Priority Data: 0250/97 7 March 1997 (07.03.97) DK</p> <p>(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CLAUSEN, Finn, Priess [DK/DK]; Delfinvej 14, DK-3450 Allerød (DK). McCLUSKEY, Klaus, Karl [DK/DK]; Sadelmagerporten 4, DK-2650 Hvidovre (DK). PREIKSCHAT, Herbert, Fritz [DK/DK]; Langkærgårdsvæj 22, DK-3460 Birkerød (DK). PEDERSEN, Søren, Bols [DK/DK]; Vesterkærsvej 7, DK-2650 Hvidovre (DK).</p> <p>(74) Agents: BAGGER-SØRENSEN, Brigitte et al.; Internationalt Patent-Bureau, Høje Taastrup Boulevard 23, DK-2630 Taastrup (DK).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: PROCESS FOR THE PREPARATION OF 2-[(2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLES AND NOVEL COMPOUNDS OF USE FOR SUCH PURPOSE</p> <div style="text-align: center;"> <p>Chemical structures:</p> <ul style="list-style-type: none"> <li>(V): 2-[(2-pyridinyl)methyl]sulfinyl-1H-benzimidazole. It consists of a benzimidazole ring system with an R<sup>2</sup> group at position 1 and an R<sup>4</sup> group at position 2. At position 5, there is a pyridinylmethylsulfinyl group (-CH<sub>2</sub>S(=O)R<sup>3</sup>) and an R<sup>5</sup> group. A substituent R<sup>n</sup> is shown at the 2-position of the pyridine ring.</li> <li>(I): 1H-benzimidazole-2-carboxamide. It has an R<sup>2</sup> group at position 1 and a carbonyl group at position 2.</li> <li>(II): 1H-benzimidazole-2-carbonyl. It has an R<sup>2</sup> group at position 1 and a carbonyl group at position 2.</li> <li>(III): 1H-benzimidazole-2,3-dioxole. It has an R<sup>2</sup> group at position 1 and a carbonyl group at position 2.</li> <li>(IV): 1H-benzimidazole-2-carboxylic acid. It has an R<sup>2</sup> group at position 1 and a carboxylic acid group (-COOH) at position 2.</li> <li>(Va): 2-[(2-pyridinyl)methyl]sulfinyl-1H-benzimidazole. It is similar to structure (V) but lacks the R<sup>n</sup> substituent at the 2-position of the pyridine ring.</li> </ul> </div>			
<p>(57) Abstract</p> <p>2-[(2-pyridinyl)methyl]sulfinyl-1H-benzimidazole derivatives of general formula (V) wherein R<sup>2</sup> represents H, OCH<sub>3</sub>, OCHF<sub>2</sub> or CF<sub>3</sub>, R<sup>3</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>, R<sup>4</sup> represents H, OCH<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, halo or nitro, R<sup>5</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>, and n is 0 or 1, or salts thereof, are prepared by a new process proceeding via novel intermediates of general formulae (I), (II), (III) and (Va) wherein R<sup>1</sup> represents branched or straight C<sub>1-8</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl, aryl, aralkyl having 1-8 C-atoms in the alkyl moiety, or a 5- or 6-membered heterocyclic group having one, two or three hetero atoms selected from nitrogen, sulfur and oxygen in the heterocyclic ring. The compounds of formula (V) are biologically active and/or may be used as intermediates in the synthesis of biologically active compounds.</p>			


**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Process for the preparation of 2-[[2-pyridinyl)methyl]sulfinyl]-1H-benzimidazoles and novel compounds of use for such purpose.

5 The present invention relates to a process for the preparation of 2-[[2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole derivatives of the general formula V



wherein

15 R<sup>2</sup> represents H, OCH<sub>3</sub>, OCHF<sub>2</sub> or CF<sub>3</sub>,

R<sup>3</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>,

R<sup>4</sup> represents H, OCH<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, halo or nitro,

R<sup>5</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>, and

n is 0 or 1,

20 and salts thereof.

Furthermore, the invention relates to novel compounds of use for such purpose.

The above mentioned compounds of formula V are biologically active and/or may be used as intermediates 25 in the synthesis of biologically active compounds.

The compounds, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (omeprazole), 2-[[[4-(2,2,2-trifluoroethoxy)-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (lansoprazole), 2-[[2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (timoprazole) and 5-difluoromethoxy-2-[[3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (pantoprazole), being known as gastric acid secretion inhibiting agents, are examples of biologically active 35 compounds of the general formula V.

With a few exceptions, the compounds of formula V wherein n is 1, are novel compounds. The present invention provides an elegant new synthesis for the preparation of these compounds, which proceeds in three steps 5 via novel cyclic intermediates and provides the compounds in excellent yields. The three steps may even be carried out in situ as a one-pot process. In an optional step of the process, the compounds of formula V, wherein n is 1, are converted into the corresponding 10 compounds of formula V, wherein n is 0, by reduction.

The unsubstituted compound of formula V, wherein n is 1, i.e. the compound 2-[[1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, is described in FR 2 567 123 A1, Example 13, yet without indication of 15 specific process details. FR 2 567 123 A1 includes no description of any other 2-[[1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazoles or their preparation. No conversion of the compound to the corresponding 2-[[2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole is 20 described either.


The compound of formula V wherein n is 1, R<sup>2</sup> and R<sup>5</sup> are hydrogen, R<sup>3</sup> is methyl and R<sup>4</sup> is 2,2,2-trifluoroethoxy, i.e. the compound 2-[[[4-(2,2,2-trifluoroethoxy)-3-methyl-1-oxido-2-pyridinyl)methyl]sulfinyl]- 25 1H-benzimidazole (lansoprazole-N-oxide), is described in ES 2 063 705 B1 as being obtained as an impurity when the compound 2-[[[4-(2,2,2-trifluoroethoxy)-3-methyl-2-pyridinyl)methyl]thio]-1H-benzimidazole is oxidized into 2-[[[4-(2,2,2-trifluoroethoxy)-3-methyl- 30 2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (lansoprazole), using m-chloroperbenzoic acid or hydrogen peroxide in the presence of vanadium compounds as oxidation agent. There is no mentioning of the N-oxide being isolated or converted into lansoprazole.

35 Besides, the compound of formula V wherein n is 1,

R<sup>3</sup> and R<sup>5</sup> represent CH<sub>3</sub>, and R<sup>2</sup> and R<sup>4</sup> represent OCH<sub>3</sub>, i.e. the compound 5-methoxy-2-[(4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (omeprazole-N-oxide), has been reported as 5 having been found as a metabolite of omeprazole in rats, CA 124:306394, Yakubutsu Dotai, 11(1), 45-56 (Japanese) 1996.

The present invention provides a new process for the preparation of 2-[(2-pyridinyl)methyl]sulfinyl]-10 1H-benzimidazole derivatives of the general formula V

15




wherein

R<sup>2</sup> represents H, OCH<sub>3</sub>, OCH<sub>2</sub>F, or CF<sub>3</sub>,  
 20 R<sup>3</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>,  
 R<sup>4</sup> represents H, OCH<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, halo or nitro,  
 R<sup>5</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>, and  
 n is 0 or 1,  
 and salts thereof,  
 25 which process comprises the steps of:

i) cyclizing a 2,3-dihydro-2-thioxo-1H-benzimidazole-1-carboxamide of the general formula I

30




wherein R<sup>1</sup> represents branched or straight C<sub>1-8</sub>-35 alkyl, C<sub>3-8</sub>-cycloalkyl, aryl, aralkyl having 1-8 C-atoms

in the alkyl moiety, or a 5- or 6-membered heterocyclic group having one, two or three hetero atoms selected from nitrogen, sulfur and oxygen in the heterocyclic ring, and

5 R<sup>2</sup> have the same meanings as defined for formula V and is located in the 5- or 6-position of the benzimidazole nucleus,

by oxidation in a suitable solvent so as to form a 1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one of 10 the general formula II,


15



wherein R<sup>1</sup> and R<sup>2</sup> are as defined above, and the R<sup>2</sup> group is located in the 6- or 7-position of the condensed ring,


20 ii) oxidizing the obtained compound of formula II so as to form a 1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one-1-oxide of the general formula III,

25




30 wherein R<sup>1</sup> and R<sup>2</sup> are as defined above, and the R<sup>2</sup> group is located in the 6- or 7-position of the condensed ring, and

iii) reacting the obtained compound of formula III with a pyridine-N-oxide of the general formula IV




wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above, in the presence of an alcoholate, so as to form a 2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazole derivative 10 of the general formula Va



wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above, and, if desired, converting a compound obtained in free form into a salt thereof, or vice versa, a compound of 20 any of the formulae I, II, III and Va, if desired, being converted into a different compound of said formula before the reaction in the next step is carried out, and furthermore, if desired,

iv) reducing the obtained compound of formula Va 25 or a salt thereof into a compound of the general formula Vb,




wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above, and, if desired, converting a compound obtained in 35 free form into a salt thereof, or vice versa.

The synthesis of addition products of the unsubstituted benzimidazolinethione and isocyanates and the cyclization of the addition products by treatment with bromine/triethylamine, sulfonylchloride or thionylchloride has been described in *Tetrahedron*, Vol. 39, No. 13, pp. 2311 - 2314, (1983), D. Martin and F. Tittelbach, "Synthesen von Benzimidazolo[1,2-d] (1,2,4)-thiadiazolinen". However, the compounds of formula II wherein R<sup>2</sup> is other than hydrogen, appear to be novel compounds and as such represent a particular aspect of the invention. Also the compounds of formula I wherein R<sup>2</sup> is other than hydrogen appear to be novel compounds and as such represent a particular aspect of the invention.

15 The oxidation of sulphenamides into sulphinamides has been described in e.g. *Houben-Weyl*, "Methoden der Organischen Chemie", Vol. E11, p. 655, (1985) and Patai, "The Chemistry of Sulphonic Acids", p. 259 and pp. 609-10 (1990). However, the compounds of formula III appear not only to be novel, but also to represent a novel cyclic structure. To our knowledge, the entire group of 1,2,4-thiadiazolo[4,5-a] "fused ring"-3(H)-one-1-oxides are compounds not having been described prior to the present invention. Thus, also the compounds of formula III represent a particular aspect of the invention.

By reaction of the novel cyclic compounds III with the pyridine-N-oxide of formula IV in the presence of an alcoholate, a ring opening takes place whereby the compounds of formula V, wherein n is 1, i.e. the compounds of the general formula Va

7



wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above, are formed.

To our knowledge, compounds of formula Va have not 10 been used for the preparation of compounds of formula Vb before, and accordingly the use of a compound of formula Va for such purpose represents a particular aspect of the invention.

The starting compounds of formula I, some of which 15 are novel compounds, may be prepared using the synthesis described in the above mentioned Tetrahedron paper, starting from known compounds and/or from novel compounds, which may be obtained using art known processes.

20 As mentioned above, R<sup>1</sup> represents branched or straight C<sub>1-8</sub>-alkyl, preferably C<sub>1-6</sub>-alkyl, such as methyl, ethyl, propyl, incl. n-propyl and i-propyl, butyl, incl. n-butyl, sec.-butyl and tert.-butyl, pentyl, incl. n-pentyl and tert.-pentyl, hexyl, heptyl 25 and octyl, C<sub>3-8</sub>-cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclohexyl, aryl, such as optionally substituted phenyl or naphthyl, aralkyl having 1-8, preferably 1-6 C-atoms in the alkyl moiety, such as optionally substituted 30 benzyl, or an optionally substituted 5- or 6-membered heterocyclic group having one, two or three hetero atoms selected from nitrogen, sulfur and oxygen in the heterocyclic ring. Specific examples of such groups are furyl, thienyl and pyridinyl. The nature of the R<sup>1</sup> 35 group is not particularly critical as long as it allows

the desired reactions to take place. A presently preferred R<sup>1</sup> group is cyclohexyl being easily obtainable through the commercially available cyclohexylisocyanate.

5 The oxidative cyclisation in step i) is carried out in a suitable solvent, such as a halogenated hydrocarbon solvent, preferably chloroform, methylene chloride, 1,1,1-trichloroethane or a mixture thereof. However, any solvent allowing the desired reaction to 10 take place may be used.

The cyclisation is carried out using an oxidation agent, such as an oxidation agent selected from bromine, chlorine and sulfonyl chloride.

If desired, a base, such as a trialkylamine base 15 and preferably triethylamine, may be added. In a presently preferred embodiment, the cyclisation is carried out using bromine as oxidation agent followed by addition of triethylamine.

In general the oxidative cyclisation will be 20 carried out at a temperature from -20°C - 70°C, and preferably from 0°C - 40°C.

In step ii) the compound of formula II is oxidized 25 into a compound of formula III using a suitable oxidation agent. As an example of suitable oxidation agents, the oxidation agents of peroxy-type, such as oxidation agents selected from peracids, alkylhydroperoxides, benzoylperoxides, hydrogenperoxide, tetraalkylammonium meta-periodates and perborates, can be mentioned. The peracids are preferably optionally substituted perbenzoic acids, such as m-chloroperbenzoic acid.

In general, the oxidation in step ii) is carried out at a temperature from -70°C - 70°C, and preferably from -20°C - 30°C.

As the oxidative cyclisation in step i), the 35 oxidation in step ii) is carried out in a suitable

solvent, such as a halogenated hydrocarbon solvent, preferably chloroform, methylene chloride, 1,1,1-trichloroethane or a mixture thereof. However, any solvent allowing the desired reaction to take place may 5 be used.

The reaction of the compound of formula III with the pyridine-N-oxide of formula IV in step iii) is carried out in the presence of an alcholate, such as an alkali or alkaline earth metal alcholate of an 10 aliphatic or alicyclic alcohol. Lithium, sodium and potassium are specific examples of the alkali metals and calcium and magnesium are specific examples of the alkaline earth metals which may be of use in the preparation of the alcholate. Methanol, ethanol, n- 15 propanol, i-propanol, n-butanol, i-butanol and t-butanol are specific examples of the aliphatic alcohols, and benzyl alcohol of the alicyclic alcohols which may be of use in the preparation of the alcholate. A presently preferred alcholate is an 20 alkali metal alcholate, particularly potassium t-butoxide.

In general, the reaction in step iii) is carried out at a temperature from -70°C - 50°C and preferably from -30°C - 30°C.

25 Examples of suitable solvents for the reaction in step iii) are solvents of alkyl- or cycloalkylether type, such as tetrahydrofuran and dioxane, although any solvent allowing the reaction to take place may be used.

30 In a particular aspect of the invention, all three steps i), ii) and iii) or the steps i) and ii), respectively ii) and iii) may be carried out in situ as a one-pot process.

If desired, a compound of formula Va or a salt 35 thereof as obtained by the above steps i), ii) and

iii), may be reduced into a compound of formula Vb using a suitable reducing agent, a compound of any of the formulae I, II, III and Va, if desired, being converted into a different compound of said formula 5 before the reaction in the next step is carried out.

As examples of reducing agents which may be of use for the reduction of a compound of formula Va into a compound of formula Vb, thiobisamines (diaminosulfanes), dialkoxy sulfanes, and catalytical reduction 10 agents such as RaNi/H<sub>2</sub> and Ru-catalysts/H<sub>2</sub> can be mentioned.

In a particularly preferred embodiment, the reduction is carried out using a thiobisamine and particularly thiobismorpholine or thiobispiperidine as 15 reducing agent in the presence of an alcohol and an acid.

Many reducing agents have been suggested for use in the reduction of pyridine-N-oxides into pyridines, cf. e.g. the survey given in Houben-Weyl, "Methoden der 20 Organischen Chemie", Vol. E7b, Part 2, (1992), pp. 543 - 557. However, as far as we know, thiobisamines have not hitherto been suggested for use in the reduction of pyridine-N-oxides into pyridines.

The thiobisamines allow for selective reduction of 25 the N-oxide group in the compounds of formula Va, whereby the compounds of formula Vb may be obtained in almost quantitative yield.

As a further advantage, the reaction takes place under mild conditions. Thus, the reduction can be 30 carried out in an alcoholic solvent, such as in a methanolic and/or ethanolic solvent. Furthermore, the reaction will usually be carried out at a temperature in the range from -10°C - 40°C, although, in principle, there is no hindrance to using temperatures outside 35 this range, such as temperatures in the ranges from

-50°C - -10°C and from 40°C - 70°C.

Usually, the thiobisamine is used in at least an equimolar ratio to the compound of formula Va, although the reaction may proceed at lower ratios such as at 5 ratios of about 0.8. There is no specific upper limit, but for economical reasons molar ratios above 5.0 will normally be avoided. Typically, the molar ratio will not exceed 2.5 and in most cases the molar ratio will be in the range from 1.0 to 1.5.

10 In a preferred embodiment, the reduction is carried out in the presence of a mineral acid, preferably hydrochloric acid and/or sulphuric acid. The hydrochloric acid may be added as a solution of hydrogen chloride in water, e.g. as concentrated hydro-15 chloric acid or as a solution of hydrogen chloride in a solvent, preferably an alcoholic solvent, such as a solution in methanol and/or ethanol. Also a solution of hydrogen bromide, e.g. in an alcohol as mentioned above, may be used.

20 In an embodiment being particularly preferred at present, the reduction is carried out in a methanolic and/or ethanolic solvent in the presence of hydrogen chloride under substantially anhydrous conditions.

The invention will now be further illustrated by 25 specific examples which, however, should not be regarded as any limitation of the scope of the invention.

#### EXAMPLES.

30

##### Preparation of starting materials.

Example A. N-Cyclohexyl-2,3-dihydro-5-methoxy-2-thioxo-1H-benzimidazole-1-carboxamide (from 4-methoxy-35 2-nitroaniline).

N-Cyclohexyl-N'-(4-methoxy-2-nitrophenyl)urea.

4-Methoxy-2-nitroaniline (150 g, 892 mmol), cyclohexylisocyanate (112 g, 892 mmol) og pyridine (45 mL) were dissolved in DMF (dimethylformamide) (1.5 L) and 5 heated to 80°C for 8 h. The formed suspension was cooled to room temperature and ethanol (0.5 L) was added. After cooling on an ice bath, the precipitate was filtered off and washed with ethanol. Drying at 50°C afforded 227 g (87 %) of the title compound as a 10 yellow product. Mp. 233-35°C.

N-Cyclohexyl-N'-(2-amino-4-methoxyphenyl)urea.

N-Cyclohexyl-N'-(4-methoxy-2-nitrophenyl)urea (50.0 g, 170 mmol) was suspended in ethanol (1.5 L) and 10% 15 Palladium on Carbon (5.0 g) was added. The mixture was reduced with hydrogen at 1 atm. and room temperature overnight. Then the reaction mixture was heated to 70°C and the catalyst filtered off. The filtrate was evaporated to 400 mL and cooled to -20°C. The precipitate was 20 filtered off, washed with ethanol and dried at 50°C to give 39.8 g (89 %) of the title compound as a white crystalline product. Mp. 187-88°C.

N-Cyclohexyl-2,3-dihydro-5-methoxy-2-thioxo-1H-25 benzimidazole-1-carboxamide.

N-Cyclohexyl-N'-(2-amino-4-methoxyphenyl)urea (104.4 g, 397 mmol) and carbondisulfide (66.4 g, 874 mmol) were heated in dry DMF (400 mL) for 41 h at 50°C. The resulting solution was cooled to room temperature 30 and added to water (1250 mL) over 1½ h. After further stirring for 2 h the precipitate was filtered off, washed with water and dried at 60°C to give 118.6 g (98 %) of the title compound as a white crystalline product. Mp. 188-90°C. Recrystallisation from acetone 35 raised the melting point to 198-201°C.

Example B. N-Cyclohexyl-2,3-dihydro-2-thioxo-1H-benzimidazole-1-carboxamide.

The title compound was synthesized from 2-mer-  
5 captobenzimidazole and cyclohexylisocyanate essentially  
following the procedure described by E. Dyer et al., J.  
Heterocyclic Chem. 6 (1969) 23-28.

Examples illustrating the process according to the  
10 invention.

Example 1. 5-Methoxy-2-[(4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methylsulfinyl]1H-benzimidazole (Omeprazole-N-oxide).

15

A. 2-Cyclohexyl-7-methoxy-1,2,4-thiadiazolo[4,5-albenzimidazole-3(2H)-one.

N-Cyclohexyl-2,3-dihydro-5-methoxy-2-thioxo-1H-benzimidazole-1-carboxamide (91.6 g, 300 mmol) (Ex. A) was suspended in chloroform (1.1 L) at room temperature. Bromine (47.9 g, 300 mmol) in chloroform (150 mL) was added over 70 min. at room temperature. Triethylamine (60.6 g, 600 mmol) was added. The formed solution was allowed to cool to room temperature over 1 h and then washed with water (2x1 L). The organic phase was dried over anhydrous sodium sulfate and evaporated in vacuum into a fat crystalline suspension. Ethanol (1.0 L) was added. After cooling to 0°C the precipitate was filtered off, washed with ethanol and dried in vacuum at 35°C to give 87.0 g (96 %) of the title compound as an off-white product. Mp. 181-4°C. Calc. for  $C_{15}H_{17}N_3O_2S$ : C:59.4%; H:5.7%; N:13.9%; S:10.6%. Found: C:59.2%; H:5.8%; N:13.6%; S:10.6%.

B. 2-Cyclohexyl-7-methoxy-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one-1-oxide.

2-Cyclohexyl-7-methoxy-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one (24.3 g, 80 mmol) (Ex. 1A) 5 was suspended in chloroform (160 mL) and cooled on an ice bath. 99% m-CPBA (m-chloroperbenzoic acid) (13.8 g, 80 mmol) was added in small portions over 45 min. at 2-5°C. Then the ice bath was replaced with a 2-propanol - ice bath. After further stirring for 20 min. cold t-10 butylmethylether (480 mL) was added over 15 min. After cooling to -9°C the precipitate was filtered off and washed with t-butylmethylether. Drying in vacuum at room temperature gave 20.6 g (81 %) of the title compound as a white product. Mp. 155-60°C.

15 Calc. for  $C_{15}H_{17}N_3O_3S$ : C:56.4%; H:5.4%; N:13.2%; S:10.0%.  
Found: C:55.9%; H:5.4%; N:12.8%; S:9.8%.

C. 5-Methoxy-2-[(4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole-N-oxide).

2-Cyclohexyl-7-methoxy-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one-1-oxide (19.2 g, 60 mmol) (Ex. 1B) was suspended in dry tetrahydrofuran (200 mL) and cooled on an ice bath. Potassium-t-butylate (20.2 g, 180 mmol) was added in portions over 30 min. After further stirring for 5 min., 4-methoxy-2,3,5-trimethylpyridine-N-oxide (8.0 g, 48 mmol) was added. The dark green reaction mixture was stirred for 20 min., whereupon acetic acid (7.2 g, 120 mmol) was added. The 25 suspension was evaporated in vacuum to about 100 mL, and the formed residue was dissolved in 1-butanoltoluene (1:4) (100 mL) - water (250 mL). After adjusting the pH to 12 with 1N sodium hydroxide the phases were separated. The water phase was slowly neutralized 30 to pH 7.5 with acetic acid, whereby the title compound 35

precipitated. After cooling to 0°C the precipitate was filtered off, washed with water and dried to give 12.8 g of crude omeprazole-N-oxide. The crude product was stirred with methanol (150 mL) for 20 min. at room 5 temperature and then cooled to -20°C. The precipitate was filtered off and dried at 60°C to give 11.1 g (64 %) of omeprazole-N-oxide as a white product. Mp. 177-8°C (dec).

Calc. for  $C_{17}H_{19}N_3O_4S$ : C:56.5%; H:5.3%; N:11.6%; S:8.9%.

10 Found: C:56.2%; H:5.4%; N:11.7%; S:9.2%.

Example 2. 5-Methoxy-2-[[[4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole N-oxide) (3 steps in situ).

15

N-Cyclohexyl-2,3-dihydro-5-methoxy-2-thioxo-1H-benzimidazole-1-carboxamide (9.16 g, 30 mmol) (Ex. A) was suspended in chloroform (100 mL) at room temperature. Bromine (4.80 g, 30 mmol) in chloroform (50 mL) 20 was added over a period of 1 h at room temperature. Triethylamine (6.06 g, 60 mmol) was added. The formed solution was cooled to room temperature and washed with water (2x150 mL). The organic phase was dried over anhydrous sodium sulfate and filtered.

25 The above solution was cooled on an ice bath. 98 % m-CPBA (5.02 g, 29 mmol) was added in portions over 25 min. After further stirring for 40 min. chloroform was distilled off in vacuum. Remaining chloroform was removed by evaporation in vacuum with toluene to give 30 a fat crystalline suspension.

The above suspension was dissolved in dry tetrahydrofuran (150 mL) and cooled on an ice bath. Potassium-t-butylyate (13.4 g, 120 mmol) was added in portions over 30 min. After further stirring for 10 min., 4-35 methoxy-2,3,5-trimethyl-pyridine-N-oxide (5.52 g, 30

mmol) was added. The dark green reaction mixture was stirred for 15 min., whereupon acetic acid was added (5.4 g, 90 mmol). The suspension was evaporated in vacuum, and the formed residue was dissolved in chloroform (100 mL) - water (100 mL). The water phase was extracted with further chloroform (100 mL). The chloroform phases were washed successively with aqueous 10% sodium chloride (50 mL). The combined chloroform phases were dried over anhydrous sodium sulfate and evaporated in vacuum. The residue was taken up in methanol (100 mL) and cooled to -20°C. The precipitate was filtered off, washed with methanol and dried at 50°C to give 4.68 g (43 % over 3 steps) of omeprazole-N-oxide as a white product. Mp. 172-3°C (dec.).

15

Example 3. 5-Methoxy-2-[(4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole-N-oxide) (from mixed isomers).

20 In a similar manner to the procedures described in examples 1 and 2, the title compound was obtained from a mixture of the N-cyclohexyl-2,3-dihydro-5- and -6-methoxy-2-thioxo-1H-benzimidazole-1-carboxamides, prepared from 2-mercaptop-5-methoxy-benzimidazole and 25 cyclohexylisocyanate, essentially following the procedure described by E. Dyer et al., J. Heterocyclic Chemistry 6 (1969). 23-28.

30 Example 4. 5-Methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole).

Pulverized omeprazole-N-oxide (3.61 g, 10.0 mmol) (Ex. 1, 2 and 3) and 4,4'-thiobismorpholine (2.65 g, 35 13.0 mmol) (synthesized from sodium thiosulfate penta-

hydrate, bromine and morpholine as described by J. L. Kice et al, J. Org. Chem. 56 (1991) 5235-6) were suspended in methanol (70 mL) and cooled on an ice bath. 2.83 N hydrogen chloride in ethanol (7.4 mL, 21.0 5 mmol) was added. After stirring for 20 min., a clear yellowish solution was obtained. 1N sodium hydroxide (20 mL) was added and the resulting solution was evaporated in vacuum to about 25 mL. To the residue was added water (100 mL) and t-butylmethylether (50 mL). 10 The pH was adjusted to 12 with 1N sodium hydroxide. After stirring for 20 min. at pH 12, the phases were separated and acetic acid was added slowly to the water phase until a pH 7.8 was obtained. After stirring at room temperature the precipitate was filtered off, 15 washed with water and dried at 50°C to give 3.24 g (94 %) of omeprazole as a beige coloured powder. Mp. 153-4°C (dec.). The FTIR-spectra of the product and an authentic sample were identical.

Calc. for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S: C:59.1%; H:5.6%; N:12.2%; S:9.3%.

20 Found: C:59.1%; H:5.6%; N:12.1%; S:9.6%.

Preparation of Omeprazole sodium salt.

30 Omeprazole (3.45 g, 10.0 mmol) was suspended in methanol (15 mL). Sodium methoxide (540 mg, 10.0 mmol) 25 was added, whereby a new precipitate was formed. After addition of t-butylmethylether (50 mL) the precipitate was filtered off, washed with t-butylmethylether and dried to give 3.7 g of omeprazole sodium salt as a white product.

30

Example 5. 5-Methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole).

35 Example 4 was repeated, but using 1,1'-thiobis-

piperidine (synthesized from sodium thiosulfate pentahydrate, bromine and piperidine as described by J. L. Kice et al, J. Org. Chem. 56 (1991) 5235-6) as the reducing agent. Yield 91%. Mp. 154-5°C (dec.).

5 Calc. for C<sub>11</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S: C:59.1%; H:5.6%; N:12.2%; S:9.3%.  
Found: C:59.1%; H:5.6%; N:12.2%; S:9.5%.

Example 6. 2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazole-N-oxide (Timoprazole-N-oxide).

10

A. 2-Cyclohexyl-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one.

N-Cyclohexyl-2,3-dihydro-2-thioxo-1H-benzimidazole-1-carboxamide (27.5 g, 100 mmol) (Ex. B) was suspended in chloroform (400 mL) at room temperature. 15 Bromine (16.0 g, 100 mmol) in chloroform (100 mL) was added over 50 min. at room temperature, whereupon triethylamine (20.2 g, 200 mmol) was added. The formed solution was cooled to room temperature and washed with 20 water (2x300 mL). The organic phase was dried over anhydrous sodium sulfate and then evaporated in vacuum (bath 25°C) into a fat crystalline suspension. Petroleum benzine (bp. 80-100°C) was added. The formed precipitate was filtered off, washed with petroleum 25 benzine and dried in vacuum at 35°C to give 24.3 g (89 %) of the title compound as an off-white product. Mp. 202-6°C.

B. 2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazole-N-oxide (Timoprazole-N-oxide) (2 steps in situ).

2-Cyclohexyl-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one (8.2 g, 30 mmol) (Ex. 6A) was dissolved in chloroform (180 mL) and cooled on an ice bath. 99% m-CPBA (5.19 g, 30 mmol) was added in portions over 25 35 min. Chloroform was distilled off in vacuum (bath

40°C), until a fat suspension was obtained. Remaining chloroform was removed by evaporation with toluene (100 mL) in vacuum.

The resulting fat suspension of crude "sulfinamide" was dissolved in dry tetrahydrofuran (150 mL) and cooled on an ice bath. Potassium-t-butylate (13.4 g, 120 mmol) was added in portions over 15 min. After further stirring for 10 min., 2-picoline-N-oxide (4.4 g, 40 mmol) was added. The resulting reaction mixture was stirred for 30 min., whereupon acetic acid (5.4 g, 90 mmol) was added. The mixture was evaporated into a fat suspension in vacuum and then methanol (180mL) was added followed by cooling on an ice bath. The precipitate was filtered off, washed with methanol and dried at 50°C to give 5.05 g (62 % over 2 steps) of timoprazole-N-oxide as an off-white product.

Mp. 187-8°C (dec.).

Calc. for  $C_{13}H_{11}N_3O_2S$ : C:57.1%; H:4.1%; N:15.4%; S:11.7%.

Found: C:57.1%; H:4.1%; N:15.0%; S:11.6%.

Example 7. 2-Cyclohexyl-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one-1-oxide.

2-Cyclohexyl-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one (21.8 g, 80 mmol) (Ex. 6A) was dissolved in chloroform (300 mL) and cooled on an ice bath. 85% m-CPBA (16.2 g, 80 mmol) dissolved in chloroform (100 mL) was added over 35 min. The ice bath was removed and the temperature was allowed to rise to room temperature over 1 h. Chloroform was distilled off in vacuum and low temperature until a fat suspension was obtained. Ethanol (250 mL) was added. After stirring on an ice bath the precipitate was filtered off and washed with cold ethanol. Drying at 30°C gave 20.1 g (87 %) of the title compound as a white product. Mp. 158-160°C.

Calc. for  $C_{14}H_{15}N_3O_2S$ : C:58.1%; H:5.2%; N:14.5%; S:11.1%.  
Found: C:58.2%; H:5.3%; N:14.4%; S:11.2%.

Example 8. 2-Cyclohexyl-1,2,4-thiadiazolo[4,5-5 albenzimidazole-3(2H)-one-1-oxide (2 steps in situ).

N-Cyclohexyl-2,3-dihydro-2-thioxo-1H-benzimidazole-1-carboxamide (68.8 g, 250 mmol) (Ex. B) was suspended in chloroform (1.0 L) at room temperature. 10 Bromine (40.0 g, 250 mmol) was added over 30 min. at 23-30°C. Triethylamine (50.5 g, 500 mmol) was added. The formed solution was cooled to room temperature and stirred for 1 h and then washed with water (2x500 mL). The organic phase was dried over anhydrous sodium 15 sulfate.

The above solution was cooled on an ice bath. 98 % m-CPBA (43.3 g, 250 mmol) dissolved in chloroform (200 mL) was added over 30 min. at 3-8°C. After further stirring for 30 min. chloroform was distilled off in 20 vacuum (bath 40°C) until a fat suspension (about 250 mL) was obtained. t-Butylmethylether (1 L) was added. After cooling on an ice bath the precipitate was filtered off and washed with t-butylmethylether. Drying at 30°C in vacuum gave 61.2 g (85 % over 2 steps) of 25 the title compound as an off-white product. Mp. 155-7°C.

Calc. for  $C_{14}H_{15}N_3O_2S$ : C:58.1%; H:5.2%; N:14.5%; S:11.1%.  
Found: C:58.6%; H:5.4%; N:14.4%; S:11.2%.

30 Example 9. 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-1-oxido-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (Lansoprazole-N-oxide).

2-Cyclohexyl-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one-1-oxide (28.9 g, 100 mmol) (Ex. 7 and 8)

was dissolved in dry tetrahydrofuran (300 mL) and cooled on an ice bath. Potassium-t-butyrate (28.0 g, 250 mmol) was added in portions over 40 min. After further stirring for 10 min. 2,3-dimethyl-4-(2,2,2-5 trifluoroethoxy)pyridine-N-oxide (13.3 g, 60 mmol) was added. The reaction mixture was stirred for 15 min, whereupon acetic acid (9.0 g, 150 mmol) was added. The mixture was evaporated in vacuum, and the formed residue was dissolved in 1-butanol-toluene (2:3) (250 10 mL) - water (250 mL) and acetic acid was added until a pH of 7.0 was obtained. The phases were separated and the organic phase was evaporated. The formed fat suspension was taken up in methanol (200 mL) and cooled on an ice bath. The precipitate was filtered off and 15 washed with methanol followed by water. Drying at 50°C gave 7.9 g of crude lansoprazole-N-oxide. The product was shortly heated to reflux in chloroform (100 mL) and then cooled to room temperature. The crystals were filtered off, washed with chloroform and dried to give 20 5.3 g (23 %) of lansoprazole-N-oxide as an off-white crystalline product. Mp. 183-3%°C (dec.).  
Calc. for  $C_{16}H_{14}F_3N_3O_3S$ : C:49.9%; H:3.7%; N:10.9%; S:8.3%  
Found: C:50.3%; H:3.8%; N:10.8%; S:8.5%.

25        Example 10.    2-[[[3-methyl-4-(2,2,2-trifluoro-  
ethoxy)-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole  
(Lansoprazole).

Lansoprazole-N-oxide (3.85 g, 10.0 mmol) (Ex. 9)  
30 and 4,4'-thiobismorpholine (2.85 g, 14.0 mmol) (synthesized from sodium thiosulfate pentahydrate, bromine and morpholine as described by J. L. Kice et al, J. Org. Chem. 56 (1991) 5235-6) were suspended in methanol (80 mL) at room temperature. 2.85 N hydrogen chloride in 35 ethanol (8.4 mL, 24 mmol) was added over 3 min. After

stirring for 90 min. the formed solution was evaporated in vacuum to about 25 mL and water (100 mL) was added slowly. The pH was adjusted to 7.5 with 1N sodium hydroxide. After stirring at room temperature the 5 formed precipitate was filtered off and washed with water. Drying at 40°C gave 3.57 g (97 %) of a 94 % pure lansoprazole. Mp. 169-70°C (dec.). Recrystallization from acetone gave analytically pure lansoprazole as a white crystalline product. Mp. 176-7°C (dec.). The 10 FTIR-spectra of the product and an authentic sample were identical.

Calc. for  $C_{16}H_{14}F_3N_3O_2S$ : C:52.0%; H:3.8%; N:11.4%; S:8.7%  
Found: C:52.2%; H:4.0%; N:11.1%; S:8.8%.

15        Example 11. 2-[[(4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.

2-Cyclohexyl-1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one-1-oxide (11.6 g, 40 mmol) (Ex. 7 and 8) 20 was suspended in dry tetrahydrofuran (150 mL) and cooled on an ice bath. Potassium-t-butylate (13.4 g, 120 mmol) was added in portions over 25 min. After further stirring for 5 min. 4-methoxy-2,3,5-trimethyl-pyridine-N-oxide (5.4 g, 24 mmol) was added. The dark 25 green solution was stirred for 30 min., whereupon acetic acid (4.8 g, 80 mmol) was added. The reaction mixture was evaporated in vacuum to a fat suspension (about 50 mL) and then 1-butanol-toluene (1:3) (80 mL) and water (150 mL) were added. The pH was adjusted to 30 12 with 11N sodium hydroxide. The water phase was washed with further 1-butanol-toluene (1:3) (80 mL) and then adjusted to pH 7.7 by slowly addition of acetic acid. The resulting suspension was cooled on an ice bath. The precipitate was filtered off and washed with 35 water. Drying at 50°C gave 7.0 g of the crude title

compound. The product was shortly stirred with methanol (80 mL) at room temperature and then cooled to -20°C. The product was filtered off, washed with methanol and dried at 50°C to give 6.3 g (59 %) of the title compound as an off-white powder. Mp. 183-4° (dec.).

Calc. for  $C_{16}H_{17}N_3O_3S$ : C:58.0%; H:5.2%; N:12.7%; S:9.7%.  
Found: C:57.9%; H:5.4%; N:12.8%; S:9.8%.

Example 12. 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.

2-[[[4-Methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (3.31 g, 10.0 mmol) (Ex. 11) and 4,4'-thiobismorpholine (2.86 g, 14.0 mmol) (synthesized from sodium thiosulfate pentahydrate, bromine and morpholine as described by J. L. Kice et al, J. Org. Chem. 56 (1991) 5235-6) were suspended in methanol (75 mL) and cooled on an ice bath. 2.83 N hydrogen chloride in ethanol (7.4 mL, 21.0 mmol) was added. The reaction was monitored by HPLC. After stirring for 1½ h and 2½ h further thiobismorpholine (0.82 g and 0.41 g) and 2.83 N hydrogen chloride in ethanol (2.8 mL and 1.4 mL) was added. After further stirring for 30 min. 1N sodium hydroxide (33 mL) was added. The reaction mixture was evaporated in vacuum to about 35 mL and then water (100 mL) and t-butylmethyl-ether (50 mL) were added. The pH was adjusted to 12 with 1N sodium hydroxide. After stirring at pH 12.0 for 5 min. the phases were separated. The water phase was washed with t-butylmethylether (50 mL) and then acetic acid was added slowly until pH 8.0. The formed suspension was extracted with 1-butanol-toluene (1:1) (120 mL) at 30°C. The organic phase was dried over anhydrous sodium sulfate and then evaporated in vacuum to about 35 35 mL. Cooling to 5°C, filtration, washing with 1-

butanol and drying at 50°C gave 2.41 g (77 %) of the title compound as a white crystalline product. Mp. 164-5°C (dec.).

Calc. for  $C_{16}H_{17}N_3O_2S$ : C:60.9%; H:5.4%; N:13.3%; S:10.2%.

5 Found: C:61.1%; H:5.6%; N:13.3%; S:10.0%.

Another crop 0.21 g (7 %) of the title compound (96 % purity) could be obtained from the mother liquor.

Example 13. 5-Methoxy-2-[[[4-chloro-3,5-dimethyl-10 1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.

The title compound was prepared in 3 steps from N-cyclohexyl-2,3-dihydro-5-methoxy-2-thioxo-1H-benzimidazole-1-carboxamide and 4-chloro-2,3,5-trimethyl-pyridine-N-oxide in 40 % yield essentially following the procedure described for omeprazole-N-oxide (Ex. 2). Mp. 188-9°C (dec.).

60MHz  $^1H$ -NMR ( $d_6$ -DMSO):  $\delta$  2.2 (s, 3H,  $CH_3$ ),  $\delta$  2.3 (s, 3H,  $CH_3$ ),  $\delta$  3.8 (s, 3H,  $CH_3$ ),  $\delta$  4.8 (broad s, 2H, 20  $CH_2$ ),  $\delta$  6.7-7.0 (m, 2H),  $\delta$  7.3-7.5 (m, 1H),  $\delta$  8.3 (1H).

Example 14. 5-Methoxy-2-[[[4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (Omeprazole N-oxide).

25

A mixture of 5-methoxy-2-[[[4-chloro-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (2.196 g, 6 mmol) (Ex. 13), potassium tert.-butylate (3.36 g, 30 mmol), tert.-butyl ammonium bromide (5.76 30 g, 18 mmol), methanol (36 mL) and dimethyl sulfoxide (12 mL) was heated to reflux for 18 h. HPLC chromatogram (area %) indicates 67 % yield of 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-1-oxido-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 6 % unconverted 5-methoxy-2-35 [[(4-chloro-3,5-dimethyl-1-oxido-2-pyridinyl)methyl] -

sulfinyl]-1H-benzimidazole.

The reaction mixture was poured into water (40 mL), and pH was adjusted to 7.0 with acetic acid (1.35 mL). Then chloroform (50 mL) was added. After separation of the water phase, the chloroform phase was washed with water (2 x 50 mL) and dried over magnesium sulfate. After removal of the magnesium sulfate by filtering, hexane in excess (50 mL) was added. The reaction mixture was left for crystallisation for 1 h, 10 after which the crystals were removed by filtering, washed with hexane (25 mL) and dried.

Yield of crude product: 844 mg of white crystals.  
Mp. 169 - 70 °C. Purity according to HPLC (area %), 90 %.

15 Calc. for  $C_{17}H_{19}N_3O_4S$ : C:56.5%; H:5.3%; N:11.6%

Found: C:55.5%; H:5.1%; N:11.3%

The NMR data correspond to those of an authentic sample.

From the mother liquor a further crop of 131 mg of 20 white crystals was isolated. Mp. 168 - 70 °C. Purity according to HPLC: 88.5 %.


Total yield 975 mg.

In the preceding the invention has been described 25 by means of specific examples of preferred embodiments. However, it will be appreciated by a person skilled in the art that various modifications can be made without deviating from the spirit and scope of the invention.

## P A T E N T C L A I M S

1. A process for the preparation of 2-[[[2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole derivatives of the general formula V

5



10

wherein

R<sup>2</sup> represents H, OCH<sub>3</sub>, OCHF<sub>2</sub> or CF<sub>3</sub>,

R<sup>3</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>,

R<sup>4</sup> represents H, OCH<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, halo or nitro,

15 R<sup>5</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>, and


n is 0 or 1,

or salts thereof,

characterized in comprising the steps of:

20 i) cyclizing a 2,3-dihydro-2-thioxo-1H-benzimidazole-1-carboxamide of the general formula I


25



wherein R<sup>1</sup> represents branched or straight C<sub>1-8</sub>-alkyl, C<sub>3-8</sub>-cycloalkyl, aryl, aralkyl having 1-8 C-atoms in the alkyl moiety, or a 5- or 6-membered heterocyclic group having one, two or three hetero atoms selected from nitrogen, sulfur and oxygen in the heterocyclic ring, and

30 R<sup>2</sup> have the same meanings as defined for formula V and is located in the 5- or 6-position of the benzimidazole nucleus,


by oxidation in a suitable solvent so as to form a 1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one of the general formula II,



10 wherein R<sup>1</sup> and R<sup>2</sup> are as defined above, and the R<sup>2</sup> group is located in the 6- or 7-position of the condensed ring,

15 iii) oxidizing the obtained compound of formula II so as to form a 1,2,4-thiadiazolo[4,5-a]benzimidazole-3(2H)-one-1-oxide of the general formula III,


20



wherein R<sup>1</sup> and R<sup>2</sup> are as defined above, and the R<sup>2</sup> group is located in the 6- or 7-position of the condensed ring, and


25 iii) reacting the obtained compound of formula III with a pyridine-N-oxide of the general formula IV

30




wherein R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above, in the presence of an alcoholate, so as to form a 2-[(2-pyridylmethyl)sulfinyl]-1H-benzimidazole derivative of

the general formula Va



wherein  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are as defined above, and, if desired, converting a compound obtained in free form into a salt thereof, or vice versa, a compound of any of the formulae I, II, III and Va, if desired, being converted into a different compound of said formula before the reaction in the next step is carried out, and furthermore, if desired.

15 iv) reducing the obtained compound of formula Va  
or a salt thereof into a compound of the general  
formula Vb.



wherein  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are as defined above,  
25 and, if desired, converting a compound obtained in  
free form into a salt thereof, or vice versa.

2. A process according to claim 1, wherein the oxidation in step i) is carried out with an oxidation agent selected from bromine, chlorine and sulfuryl chloride.

3. A process according to claim 1 or 2, wherein the oxidation in step i) is followed by addition of a trialkylamine base, preferably triethylamine.

4. A process according to one or more of the 35 preceding claims, wherein the oxidation in step i) is

carried out at a temperature from -20°C - 70°C, preferably from 0°C - 40°C.

5. A process according to one or more of the preceding claims, wherein the oxidation in step ii) is  
5 carried out using a peroxy-type oxidation agent.

6. A process according to claim 5, wherein the peroxy-type oxidation agent is selected from peracids, preferably optionally substituted perbenzoic acids, alkylhydroperoxides, benzoylperoxides, hydrogenper-  
10 oxide, tetraalkylammonium meta-periodates and perborates.

7. A process according to one or more of the preceding claims, wherein the oxidation in step ii) is carried out at a temperature from -70°C - 70°C, prefer-  
15 ably from -20°C - 30°C.

8. A process according to one or more of the preceding claims, wherein the alcoholate used in step iii) is an alkali metal alcoholate, preferably potassium t-butoxide.

20 9. A process according to one or more of the preceding claims, wherein the reaction in step iii) is carried out at a temperature from -70°C - 50°C, prefer-  
ably from -30°C - 30°C.

10. A process according to one or more of the  
25 preceding claims, wherein the steps i) and ii), the  
steps ii) and iii) or the steps i), ii) and iii) are carried out in situ.

11. A process according to one or more of the preceding claims, wherein the reduction in step iv) is  
30 carried out using a thiobisamine, dialkoxyulfane,  
RaNi/H<sub>2</sub> or Ru-catalyst/H<sub>2</sub> as reducing agent.

12. A process according to claim 11, wherein the reduction in step iv) is carried out using a thiobis-  
amine as reducing agent.

35 13. A process according to claim 12, wherein the


thiobisamine is used in a molar ratio to the compound of formula (Va) of 0.8 - 5.0, particularly in a molar ratio of 1.0 - 2.5 and preferably in a molar ratio of 1.0 - 1.5.

5 14. A process according to claim 12 or 13, wherein the reduction is carried out in an alcoholic solvent, preferably in a methanolic and/or ethanolic solvent.

10 12 - 14, wherein the reduction is carried out in the presence of a mineral acid, preferably hydrochloric acid and/or sulphuric acid.

15 16. A process according to one or more of claims 12 - 15, wherein the reduction is carried out at a temperature in the range from -50°C - 70°C, preferably in the range from -10°C - 40°C.

17. A compound of the general formula Va



wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above, or a salt thereof, with the provisos that R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are not all hydrogen, that when R<sup>3</sup> is methyl and R<sup>4</sup> is 2,2,2-trifluoroethoxy, then R<sup>2</sup> and R<sup>5</sup> are not both hydrogen, and that when R<sup>3</sup> and R<sup>5</sup> are both CH<sub>3</sub>, then R<sup>2</sup> and R<sup>4</sup> are not both OCH<sub>3</sub>.


30 18. A compound according to claim 17, wherein R<sup>2</sup> represents OCHF<sub>2</sub>, R<sup>3</sup> and R<sup>4</sup> represent OCH<sub>3</sub> and R<sup>5</sup> represents H.

19. A compound according to claim 17, wherein R<sup>2</sup> represents OCH<sub>3</sub>, R<sup>3</sup> and R<sup>5</sup> represent CH<sub>3</sub> and R<sup>4</sup> represents Cl.

31

20. A compound of the general formula III,


5



wherein R<sup>1</sup> and R<sup>2</sup> are as defined above, and the R<sup>2</sup> group is located in the 6- or 7-position of the condensed ring.

21. A compound of the general formula II,


15



wherein R<sup>1</sup> and R<sup>2</sup> are as defined in claim 20, with the proviso that R<sup>2</sup> is other than H, and wherein the R<sup>2</sup> group is located in the 6- or 7-position of the condensed ring.

22. A compound of the general formula I,

25




wherein R<sup>1</sup> and R<sup>2</sup> are as defined in claim 21.

30 23. A compound according to claim 20, 21 or 22, wherein R<sup>1</sup> is cyclohexyl.

24. The use of a compound of the general formula  
Va


32



wherein

R<sup>2</sup> represents H, OCH<sub>3</sub>, OCHF<sub>2</sub> or CF<sub>3</sub>,R<sup>3</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>,10 R<sup>4</sup> represents H, OCH<sub>3</sub>, OCH<sub>2</sub>CF<sub>3</sub>, halo or nitro, andR<sup>5</sup> represents H, CH<sub>3</sub> or OCH<sub>3</sub>,or a salt thereof, for the preparation of a compound of  
the general formula Vb

15

20 wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as defined above, or a  
salt thereof.

# INTERNATIONAL SEARCH REPORT

Int. onal Application No  
PCT/DK 98/00059

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C07D401/12 C07D235/28 C07D513/04

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 484 265 A (GENESIS PARA LA INVESTIGACION ;ESTEVE QUIMICA SA (ES)) 6 May 1992 * see the whole document; in particular page 24 - page 25, examples 9 and 10 * ---	1,11-19, 24
A	D. MARTIN ET AL.: "Acylierung von Heterocyclen mit Kohlensäurederivaten-III". TETRAHEDRON, (INCL TETRAHEDRON REPORTS), vol. 39, no. 13, 1983, OXFORD GB, pages 2311-2314, XP002039564 cited in the application * see the whole document; in particular page 2311, scheme 1 *	1-7, 21-23
A	DD 231 787 A (AKADEMIE DER WISSENSCHAFTEN DER DDR) 8 January 1986 see the whole document ---	1,8-10, 20 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

1

Date of the actual compilation of the international search	Date of mailing of the international search report
12 May 1998	03/06/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer  Fink, D

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 98/00059

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	H. KAGAMI ET AL.: "Deoxygenation of Amine N-Oxides or C-Nitroso Compounds by Dialkyl Sulfoxylates" JOURNAL OF ORGANIC CHEMISTRY, vol. 43, no. 6, 17 March 1978, EASTON US, pages 1267-1268, XP002039565 see the whole document -----	1,11-16

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/DK 98/00059

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0484265 A	06-05-92	NONE	
DD 231787 A		NONE	